4 results
Primary: To evaluate the efficacy of tisagenlecleucel therapy as measured by overall response rate by investigator assessment.Secondary: Duration of response, event free survival, relapse free survival, overall survival, safety, kinetics,…
Primary: - To evaluate the efficacy of tisagenlecleucel therapy as measured by the overall survival (OS)- To evaluate the efficacy of tisagenlecleucel therapy as measured by the 5- year disease-free survival (DFS) without censoring for new…
To compare tisagenlecleucel treatment strategy to SOC treatment strategy with respect to delaying the composite event of disease progression / stable disease at or after the week 12 assessment; or death at any time.
To demonstrate superior efficacy and non-inferior safety of the SELUTION SLR 014 DEB compared to PTA (uncoated balloon) in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.